News Quantified

PIRS – pieris pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer [Yahoo! Finance]

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.

Form SCHEDULE 13D PALVELLA THERAPEUTICS, Filed by: Kaupinen Wes

Form SCHEDULE 13G PALVELLA THERAPEUTICS, Filed by: Samsara BioCapital, L.P.

Form SCHEDULE 13G PALVELLA THERAPEUTICS, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC

Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Wessel Tadd S.

Form 3 PALVELLA THERAPEUTICS, For: Dec 13 Filed by: Korenberg Matthew E

Top News Gainers

3/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. 34.2%

7/30 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. 13.7%

7/26 Form 4 PIERIS PHARMACEUTICALS, For: Jul 25 Filed by: Richman Michael 12.2%

11/5 Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 11.5%

5/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%

3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 9.7%

11/4 Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019 9.0%

3/23 Pieris Pharmaceuticals Provides Update on Servier Collaboration 8.1%

11/13 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 7.9%

5/10 Form 10-Q PIERIS PHARMACEUTICALS, For: Mar 31 7.3%

Top News Decliners

3/12 Pieris Pharmaceuticals Reports Full-Year 2019 Financial Results And Provides Corporate Update -26.8%

9/27 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 27 -18.5%

9/26 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -17.1%

11/12 Form 424B5 PIERIS PHARMACEUTICALS, -15.5%

3/18 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.9%

3/27 Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -11.1%

12/4 Form S-3 PIERIS PHARMACEUTICALS, -9.7%

3/13 Form 10-K PIERIS PHARMACEUTICALS, For: Dec 31 -8.8%

7/31 Form 8-K PIERIS PHARMACEUTICALS, For: Jul 31 -8.7%

9/23 Form 8-K PIERIS PHARMACEUTICALS, For: Sep 20 -8.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day